Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 46 for:    SIR-Spheres

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02602327
Recruitment Status : Recruiting
First Posted : November 11, 2015
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).

Condition or disease Intervention/treatment Phase
Colon Cancer Rectal Cancer Liver Metastases Drug: Tas-102 Device: SIR-Sphere Phase 1

Detailed Description:
Randomized studies have demonstrated that Tas-102 has single agent activity against chemotherapy refractory colorectal cancer. A recent pre-clinical study has shown that Tas-102 may have activity as a radiation sensitizer in bladder cancer cell lines. Benefit of single agent Tas-102 against chemotherapy refractory colon cancer and the drug's promise a radiosensitizer make Tas-102 a potential candidate drug for testing in combination with radioembolization using Yttrium-90 resin microspheres in patients with liver-dominant chemotherapy-refractory mCRC. This is a phase I dose escalation study with a dose expansion arm designed to evaluate safety of the combination of Tas-102 and radioembolization using 90Y resin microspheres for patients with chemotherapy-refractory colon or rectal adenocarcinoma metastatic to the liver.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
Actual Study Start Date : June 27, 2016
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Arm Intervention/treatment
Experimental: Tas-102 and radioembolization
Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
Drug: Tas-102
Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
Other Name: Lonsurf

Device: SIR-Sphere
20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
Other Name: Yttrium-90 (Y90; 90Y) resin microspheres




Primary Outcome Measures :
  1. Determine dose limiting toxicities (DLT) [ Time Frame: 56 days ]
    Any adverse events grade ≥ 3 will be reviewed by the treating interventional radiologist and medical oncologist within 24 hours of being informed event. If none of the 3 patients in a cohort experiences a DLT, another 3 patients will be treated at the next higher dose level. However, if 1 of the first 3 patients experiences a DLT, 3 more patients will be treated at the same dose level. The dose escalation will continue until at least 2 patients among a cohort of 3-6 patients experience DLTs (i.e., ≥ 33% of patients with a dose-limiting toxicity at that dose level) or until 3-6 patients had been treated at TAS-102 dose of 35mg/m2 per day in 2 divided doses (up to a maximum of 80 mg per dose) administered concurrently with radioembolization cycles 1 and 2 without experiencing a DLT. DLT window will be 56 days (cycle 1, day 1 to cycle 2, day 28). Dose limiting toxicity will be reached when one of the clinical and/or laboratory parameters are met

  2. Maximum tolerated dose (MTD) [ Time Frame: Up to 4 years ]
    Traditional 3+3 design will be used to determine the recommended dose for the dose expansion phase will be defined as the dose level just below this toxic dose level.


Secondary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: Up to 4 years ]
    Radiographic overall response rate (measured in accordance to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) using imaging. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): 30% decrease in the sum of the longest diameter of target lesionsStable Disease (SD): Small changes that do not meet the criteria for CR, PR, or Progressive Disease (PD): 20% increase in the sum of the longest diameter of target lesions. ORR will be defined as a ratio of the number of patients who demonstrated complete response (CR) or partial response (PR) to the number of all evaluated patients.

  2. Progression-free survival (PFS) [ Time Frame: Up to 4 years ]
    PFS will be defined as a time period that started at enrollment, during which a patient neither progressed nor died based on radiographic response.

  3. Hepatic progression-free survival (HPFS) [ Time Frame: Up to 4 years ]
    HPFS will be defined as a time period that started at enrollment, during which a patient neither progressed in the liver nor died based on radiographic response.

  4. Extrahepatic progression free survival (EHPFS) [ Time Frame: Up to 4 years ]
    EHPFS will be defined as a time period that started at enrollment, during which a patient neither progressed outside the liver nor died based on radiographic response

  5. Overall survival (OS) [ Time Frame: Up to 12 months ]
    Overall Survival will be analyzed 12 months after the last patient is enrolled. Overall survival will be assessed using a two-sided, log-rank test. The survival function will be estimated using the Kaplan-Meier product limit method. In addition, two-sided 95% confidence intervals for the median overall survival will be computed

  6. Biomarker response [ Time Frame: Up to 4 years ]
    Proportion of patients with carcinoembryonic antigen (CEA) response with ≥ 50% decline from baseline (in patients with baseline level ≥ 3.2) post combination therapy with Tas-102 and 90Y radioembolization. Maximum percent change will be calculated. CEA level will only be followed for participants with elevated level (≥3.2) at baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 18 years of age or older, and of any ethnic or racial group.
  2. Diagnosis of unresectable metastatic colorectal adenocarcinoma with liver-dominant bilobar disease. Diagnosis may be made by histo- or cyto-pathology, or by clinical and imaging criteria.
  3. Disease progression or intolerance to at least two prior Food and Drug Administration-approved therapeutic regimens.
  4. If extrahepatic disease is present, it must be asymptomatic.
  5. If a primary tumor is in place, it must be asymptomatic.
  6. Measurable target tumors using standard imaging techniques (RECIST v. 1.1 criteria).
  7. Tumor replacement < 50% of total liver volume.
  8. Current Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 through screening to first treatment on study.
  9. Completion of prior systemic therapy at least 14 days prior to enrollment.
  10. Able to understand informed consent.

Exclusion Criteria:

  1. At risk of hepatic or renal failure

    • Serum creatinine > 1.5 mg/dl
    • Serum bilirubin > 1.3 mg/ml
    • Albumin < 2.0 g/dL
    • Aspartate and/or alanine aminotransferase level > 5 times upper normal limit
    • Any history of hepatic encephalopathy
    • Cirrhosis or portal hypertension
    • Clinically evident ascites (trace ascites on imaging is acceptable)
  2. Contraindications to angiography and selective visceral catheterization

    • Any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
    • Severe allergy or intolerance to contrast agents, narcotics, or sedatives that cannot be managed medically
  3. Symptomatic lung disease
  4. Prior therapy with Tas-102.
  5. Contraindications to Tas-102

    • Absolute neutrophil count < 1,500/μl
    • Platelet count < 75,000/μl
    • Allergy or intolerance to Tas-102
  6. Unresolved toxicity of greater than or equal to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade 2 due to prior therapies.
  7. Evidence of potential delivery of

    • Greater than 30 Gy absorbed dose of radiation to the lungs during a single 90Y resin microsphere administration; or
    • Cumulative delivery of radiation to the lungs > 50 Gy over multiple treatments.
  8. Evidence of any detectable Tc-99m macro aggregated albumin flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow.
  9. Previous radiation therapy to the lungs and/or to the upper abdomen
  10. Any prior arterial liver-directed therapy, including chemoembolization, bland embolization, and 90Y radioembolization
  11. Any intervention for, or compromise of the ampulla of Vater
  12. Active uncontrolled infection. Presence of latent or medication-controlled HIV and/or viral hepatitis is allowed.
  13. Significant extrahepatic disease

    • Symptomatic extrahepatic disease (including primary tumor, if unresected).
    • Greater than 10 pulmonary nodules (each < 20 mm in diameter) or combined diameter of all pulmonary nodules > 15 cm.
    • Peritoneal carcinomatosis
  14. Life expectancy less than 3 months
  15. Pregnant or lactating female
  16. In the investigator's judgment, any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of radioembolization or Tas-102.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02602327


Contacts
Layout table for location contacts
Contact: Alex Milloy (415) 502-3310 Alexandra.Milloy@ucsf.edu

Locations
Layout table for location information
United States, California
University of California San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Alex Milloy    415-502-3310    Alexandra.Milloy@ucsf.edu   
Principal Investigator: Nicholas Fidelman, MD         
Sponsors and Collaborators
University of California, San Francisco
Investigators
Layout table for investigator information
Principal Investigator: Nicholas Fidelman, MD University of California, San Francisco
Principal Investigator: Katherine Van Loon, MD University of California, San Francisco

Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT02602327     History of Changes
Other Study ID Numbers: 16452
NCI-2017-01321 ( Registry Identifier: NCI Clinical Trials Reporting Program (CTRP) )
First Posted: November 11, 2015    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of California, San Francisco:
radioembolization
Yttrium-90
90Y
Resin microspheres
Tas-102
Lonsurf
SIR-Sphere
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Liver Neoplasms
Neoplastic Processes
Neoplasms
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases